CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Bad Toelz, Germany

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

    This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose. There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period. Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.

    Phase

    3

    Span

    147 weeks

    Sponsor

    Celldex Therapeutics

    Langenau, Baden-Württemberg

    Recruiting

  • A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

    Phase

    3

    Span

    97 weeks

    Sponsor

    Alumis Inc

    Langenau

    Recruiting

  • A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared with Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa

    Phase

    3

    Span

    109 weeks

    Sponsor

    MoonLake Immunotherapeutics AG

    Langenau

    Recruiting

  • A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting

    Phase

    N/A

    Span

    241 weeks

    Sponsor

    AbbVie

    Langenau

    Recruiting

  • A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

    Phase

    3

    Span

    142 weeks

    Sponsor

    Janssen Research & Development, LLC

    Langenau

    Recruiting

  • A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis

    Phase

    3

    Span

    197 weeks

    Sponsor

    Janssen Research & Development, LLC

    Langenau

    Recruiting

  • Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis

    Phase

    N/A

    Span

    262 weeks

    Sponsor

    Sanofi

    Langenau

    Recruiting

  • Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

    Phase

    3

    Span

    109 weeks

    Sponsor

    Incyte Corporation

    Langenau

    Recruiting

  • A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

    Phase

    2

    Span

    72 weeks

    Sponsor

    Janssen Research & Development, LLC

    Langenau

    Recruiting

  • A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

    Phase

    3

    Span

    201 weeks

    Sponsor

    Janssen Research & Development, LLC

    Langenau

    Recruiting

1-10 of 11
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information